Acne inversa-like skin lesions as a potential adverse event during vemurafenib therapy

2016 ◽  
Vol 14 (4) ◽  
pp. 427-428 ◽  
Author(s):  
Alexander Thiem ◽  
Rebecca Mergler ◽  
Hermann Kneitz ◽  
Gerhard Weyandt ◽  
Matthias Goebeler ◽  
...  
Keyword(s):  
Adverse Event ◽  
Skin Lesions ◽  
Acne Inversa ◽  
Potential Adverse Event

scholarly journals Evaluating the safety of β-interferons in MS

Neurology ◽  
2017 ◽  
Vol 88 (24) ◽  
pp. 2310-2320 ◽  
Author(s):  
Hilda J.I. de Jong ◽  
Elaine Kingwell ◽  
Afsaneh Shirani ◽  
Jan Willem Cohen Tervaert ◽  
Raymond Hupperts ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
British Columbia ◽  
Adverse Event ◽  
Adverse Events ◽  
Conditional Logistic Regression ◽  
Fold Increase ◽  
Incidence Rates ◽  
Incidence Density ◽  
Cohort Entry ◽  
Potential Adverse Event

Objective:To examine the association between interferon-β (IFN-β) and potential adverse events using population-based health administrative data in British Columbia, Canada.Methods:Patients with relapsing-remitting multiple sclerosis (RRMS) who were registered at a British Columbia Multiple Sclerosis Clinic (1995–2004) were eligible for inclusion and were followed up until death, absence from British Columbia, exposure to a non–IFN-β disease-modifying drug, or December 31, 2008. Incidence rates were estimated for each potential adverse event (selected a priori and defined with ICD-9/10 diagnosis codes from physician and hospital claims). A nested case-control study was conducted to assess the odds of previous IFN-β exposure for each potential adverse event with at least 30 cases. Cases were matched by age (±5 years), sex, and year of cohort entry, with up to 20 randomly selected (by incidence density sampling) controls. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated with conditional logistic regression adjusted for age at cohort entry.Results:Of the 2,485 eligible patients, 77.9% were women, and 1,031 were treated with IFN-β during follow-up. From the incidence analyses, 27 of the 47 potential adverse events had at least 30 cases. Patients with incident stroke (ORadj 1.83, 95% CI 1.16–2.89), migraine (ORadj 1.55, 95% CI 1.18–2.04), depression (ORadj 1.33, 95% CI 1.13–1.56), and hematologic abnormalities (ORadj 1.32, 95% CI 1.01–1.72) were more likely to have previous exposure to IFN-β than controls.Conclusions:Among patients with RRMS, IFN-β was associated with a 1.8- and 1.6-fold increase in the risk of stroke and migraine and 1.3-fold increases in depression and hematologic abnormalities.

“Nail loss after teriflunomide treatment: A new potential adverse event”

2017 ◽  
Vol 18 ◽  
pp. 170-172 ◽  
Author(s):  
L. Mancinelli ◽  
P. Amerio ◽  
M. di Ioia ◽  
V. Di Tommaso ◽  
G. De Luca ◽  
...  
Keyword(s):  
Adverse Event ◽  
Potential Adverse Event

scholarly journals Efficacy of Spinosad Tablets Administered to a Colony of 15 Indoor Cats Naturally Infested with Fleas

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Marie-Christine Cadiergues ◽  
Charline Pressanti
Keyword(s):  
Adverse Event ◽  
Skin Lesions ◽  
Severity Scale ◽  
Allergic Dermatitis ◽  
Flea Allergy Dermatitis ◽  
Flea Allergy ◽  
Lesion Severity

The aims of the study were (i) to describe adult fleas distribution in a strictly indoor cat colony composed of cats with flea allergy dermatitis (FAD) and non-FAD cats and (ii) to evaluate the efficacy of spinosad used alone. Skin lesions were scored according to the SCORing Feline Allergic Dermatitis lesion severity scale (SCORFAD) on days 0, 15, 30, 45, 60, and 90. Cats were combed prior to the treatment (days 0, 30, and 60) and on days 15, 45, and 90; collected fleas were replaced on the animals. All cats received flavored spinosad tablets (Comfortis) at a dosage of 50–75 mg/kg on days 0, 30, and 60. Cats were fed immediately afterwards. On day 0, a total of 60 fleas were collected (mean: 4±4). Cats with FAD had a SCORFAD of 6, 8, 12, and 13 and harbored 0, 2, 1, and 0 fleas, respectively. Tablets were taken voluntarily by 8, 11, and 12 cats on days 0, 30, and 60, respectively. No adverse event was recorded. From day 15 to day 90, no fleas could be collected. SCORFAD was reduced by 40%, 71%, 80%, 89%, and 98% on days 15, 30, 45, 60, and 90, respectively.

scholarly journals Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy

2020 ◽  
Vol 7 (8) ◽  
Author(s):  
Axel A Vazquez Deida ◽  
Katherine C Shihadeh ◽  
Candice R Preslaski ◽  
Heather L Young ◽  
David L Wyles ◽  
...  
Keyword(s):  
Adverse Event ◽  
Single Dose ◽  
Antibiotic Therapy ◽  
Bacterial Infection ◽  
Hospital Discharge ◽  
Clinical Success ◽  
Potential Adverse Event ◽  
Vulnerable Patients ◽  
Hospital Days

Abstract Twenty-seven patients receiving prolonged inpatient antibiotic therapy for a serious bacterial infection received a single dose of dalbavancin 7–10 days before the planned end date to facilitate earlier hospital discharge. Eighty-one percent met criteria for clinical success, 7% experienced a potential adverse event, and 182 hospital days were averted.

PO-74 Allergic skin lesions are a rare adverse event under anticoagulant therapy with fondaparinux – results of a prospective investigation

2010 ◽  
Vol 125 ◽  
pp. S186
Author(s):  
M. Schindewolf ◽  
J. Scheuermann ◽  
H. Kroll ◽  
J. Garbaraviciene ◽  
C. Hecking ◽  
...  
Keyword(s):  
Adverse Event ◽  
Anticoagulant Therapy ◽  
Skin Lesions ◽  
Allergic Skin ◽  
Prospective Investigation

scholarly journals A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110349 ◽  
Author(s):  
Madison Ward ◽  
Khalad Maliyar ◽  
Melinda Gooderham
Keyword(s):  
Adverse Event ◽  
Case Report ◽  
Early Detection ◽  
Signaling Pathway ◽  
Conventional Therapy ◽  
Critical Role ◽  
Interleukin 17 ◽  
Biologic Treatment ◽  
Potential Adverse Event ◽  
Aphthous Ulcers

The interleukin-17 signaling pathway plays a critical role in the pathogenesis of psoriasis. By inhibiting this pathway, there is a reduction in the severity of psoriasis and many patients achieve clear skin. We present two individuals, a 34-year-old male and a 40-year-old female, who developed aphthous ulcers on the oral mucosa and oral and vulvar mucosa, respectively, while undergoing treatment with interleukin-17 inhibitors. The ulcers did not respond to conventional therapy, including topical corticosteroids and nystatin 100,000 unit/mL oral suspension. Both patients underwent biopsies which confirmed the diagnosis of ulcer. Once confirmed, the interleukin-17 inhibitor was discontinued and the ulcers resolved in both cases. As we see biologic treatment, specifically interleukin-17 inhibitor, becoming more popular for the treatment of psoriasis, it is important for physicians to be aware of this potential adverse event. Early detection and intervention are important to avoid complications that can develop from rare but often painful ulcers.

Acitretin-Induced Hepatitis: When to Monitor Cholestatic Enzymes

2015 ◽  
Vol 19 (2) ◽  
pp. 115-120 ◽  
Author(s):  
Maxwell B. Sauder ◽  
Loretta Cheung ◽  
Jennifer Beecker
Keyword(s):  
Clinical Trials ◽  
Alkaline Phosphatase ◽  
Adverse Event ◽  
Literature Review ◽  
Unusual Presentation ◽  
Potential Adverse Event ◽  
Hepatocyte Injury ◽  
Hepatocyte Damage ◽  
Mixed Pattern ◽  
Elevated Transaminases

Importance Acitretin is a systemic retinoid that is used in dermatology for a variety of conditions. A well-recognized potential adverse event from acitretin is elevated transaminases, indicating acute hepatocyte damage. Less well known is the possible cholestatic injury that can occur, signaled by elevated γ-glutamyltransferase (GGT) and alkaline phosphatase (ALP). Observations Our patient presented with an acute acitretin-induced hepatitis with a mixed pattern of elevated transaminases as well as GGT and ALP. A literature review demonstrated that most cases of acitretin-induced hepatitis, outside clinical trials, describe patients with a similar mixed hepatitis pattern. Conclusions This is the first literature review on acitretin-induced hepatitis. Although acitretin-induced hepatoxicity is rare, the seemingly unusual presentation of a mixed pattern of hepatocyte injury and cholestasis may be more common than previously thought. The findings should encourage clinicians not only to monitor transaminases but also to consider measuring cholestatic enzymes (ALP/GGT) in patients with transaminase abnormalities.

scholarly journals New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19

2021 ◽  
pp. 103321
Author(s):  
Yara D Fragoso ◽  
Sidney Gomes ◽  
Marcus Vinicius M Gonçalves ◽  
Euldes Mendes Junior ◽  
Bianca Etelvina S de Oliveira ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Event ◽  
Neuromyelitis Optica ◽  
Potential Adverse Event
Sign in / Sign up

Export Citation Format

Share Document